42494-73-5

基本信息
化合物 BPV(PHEN)
BISPEROXO(1,10-菲咯啉)氧釩酸鉀(V)三水合物
K[VO(O2)2C12H8N2] 3H2O
bpV(phen) - CAS 42494-73-5 - Calbiochem
POTASSIUM BISPEROXO(1,10-PHENANTHROLINE)OXOVANADATE (V)
Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (V) trihydrate
Vanadate(1-), oxodiperoxy(1,10-phenanthroline-κN1,κN10)-, potassium (1:1), (PB-7-23-111′1′3)-
常見問題列表
IC50: 38 nM (PTEN), 343 nM (PTP-β) and 920 nM (PTP-1B)
Parasite
Leishmania
Apoptosis
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment causes a further decrease of cell viability in H/R-injured H9c2 cells.
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment increases the apoptosis of H/R-injured H9c2 cells.
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment significantly promotes the accumulation of cytoplasmic Cytochrome C in H/R-injured H9c2 cells.
After stimulation of bpV(phen), PTEN-induced putative kinase protein 1 (PINK1)/Parkin-mediated mitophagy is inhibited.
bpV(phen) is an insulin-mimetic agent following insulin-receptor tyrosine kinase hyperphosphorylation and activation.
Cell Viability Assay
Cell Line: | Hypoxia/reoxygenation (H/R)-injured H9c2 cells |
Concentration: | 5 μM |
Incubation Time: | 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) |
Result: | Caused a further decrease of cell viability. |
Apoptosis Analysis
Cell Line: | Hypoxia/reoxygenation (H/R)-injured H9c2 cells |
Concentration: | 5 μM |
Incubation Time: | 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) |
Result: | Increased the apoptosis of H/R-injured H9c2 cells. |
Western Blot Analysis
Cell Line: | Hypoxia/reoxygenation (H/R)-injured H9c2 cells |
Concentration: | 5 μM |
Incubation Time: | 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) |
Result: | Showed an increased release of Cytochrome C. |
bpV(phen) (5 mg/kg; intraperitoneal injection; daily; for 38 days; male BALB/c nude (nu/nu) athymic mice) treatment causes a significant reduction in average tumor volume.
Animal Model: | Male BALB/c nude (nu/nu) athymic mice (6-7 weeks old) injected with PC-3 cells |
Dosage: | 5 mg/kg |
Administration: | Intraperitoneal injection; daily; for 38 days |
Result: | Caused a significant reduction in average tumor volume. |